Sonoma Pharmaceuticals, Inc.

SNOAReported to SECin USCIK 0001367083Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 6. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 6
Form 4 lines at Sonoma Pharmaceuticals, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Weigerstorfer Philippe—Award—10,000 sharesJul 9, 2026Weigerstorfer Philippe—Award · Jul 9Award10,000Jul 9, 2026
Trombly Amy MossChief Executive OfficerAwardnothing paid10,000 sharesJul 9, 2026Trombly Amy MossChief Executive Officernothing paidAward · Jul 9Award10,000Jul 9, 2026
MCLAUGHLIN JOHN—Award—10,000 sharesJul 9, 2026MCLAUGHLIN JOHN—Award · Jul 9Award10,000Jul 9, 2026
Jacoby Vanessa—Award—10,000 sharesJul 9, 2026Jacoby Vanessa—Award · Jul 9Award10,000Jul 9, 2026
DVONCH JEROME JChief Financial OfficerAwardnothing paid10,000 sharesJul 9, 2026DVONCH JEROME JChief Financial Officernothing paidAward · Jul 9Award10,000Jul 9, 2026